Navigation Links
Par Pharmaceutical Companies Reports Second Quarter 2011 Results
Date:8/3/2011

$84.5 million in the first quarter 2011. The decrease is due to primarily to the voluntary withdrawal of clonidine in the second quarter and the seasonality of hydrocodone/chlorpheniramine.
  • Megace® ES: Net sales were $14.1 million for the second quarter compared to $14.1 million in the first quarter.

  • Nascobal® B12 Nasal Spray: Net sales were $6.3 million for the second quarter compared to $3.9 million in the first quarter.  The increase was due, in part, to a shortage of a competing vitamin B12 intramuscular injection product.

  • Revenues and gross margin for the second quarter 2011 were $224.2 million and $99.0 million, respectively, compared to $233.0 million in net sales and $109.7 million in gross margin during the prior quarter (Q1 2011). The gross margin rate on the Company's consolidated product portfolio decreased to 44.2% versus 47.1% in the first quarter 2011.  The decrease was due primarily to the non-recurrence of the first quarter launches of propafenone and amlodipine/benazepril and the second quarter launch of lower margin budesonide.  2Q 20111Q 2011$%$%Key Par (Generic) Products (1)(2)$   40.7

    32.3%$   50.6

    40.4%All other Par (Generic)43.3

    56.5%42.0

    49.6%Total Par (Generic)$   84.0

    41.5%$   92.6

    44.1%Strativa (Branded) Products$   15.0

    69.1%$   17.1

    73.7%Total (All Products) $   99.0

    44.2%$ 109.7

    47.1%1. Q211 Key Par Products is comprised of Metoprolol, Budesonide EC, Sumatriptan, Propafenone, Amlodipine/benazapril, Meclizine.

    2. Q111 Key Par Products does not include Budesonide EC as it was launched in Q2.Operating ExpensesExcluding the one-time restructuring charge of $27.7 million, total operating expenses decreased during the second quarter of 2011 as compared to the prior quarter as follows:

  • Research and development expenses were $8.1 million in the seco
    '/>"/>

  • SOURCE Par Pharmaceutical Companies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
    2. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
    3. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
    4. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    5. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
    6. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
    7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
    9. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
    10. Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders
    11. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... , September 3, 2015 ... compounds, Organosulfurs, Organic acids, Phenolics, and Others) and by ... beverage, Paints & coatings, and Others) - Global Trends ... segments the Biocides Market with an analysis and forecast ... value. Browse   88 tables and ...
    (Date:9/2/2015)... , Sept. 2, 2015 About ... artificial implants used to replace, augment, or repair ... a wide range of applications including cosmetic, spinal, ... are made of different materials such as polymers, ... the global implantable medical devices market to grow ...
    (Date:9/2/2015)... LONDON , Sept. 2, 2015 The quantum ... industry, and the key market based on the product includes ... solar cell, chip, sensor, lighting, battery and energy storage, QD ... of different applications for the quantum dot market. The report ... North America , Europe ...
    Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5Global Implantable Medical Devices Market 2015-2019 2Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2
    ... 2011 University Hospitals (UH) Seidman Cancer Center, ... opens to patients on June 6. The ten-story, ... treatments and technology – all in a patient-centered, ... ) The $260 million, 375,000-square-foot hospital ...
    ... N.J., June 6, 2011 Bayer HealthCare Pharmaceuticals Inc. ... pharadin in SYM ptomatic P rostate ... which is exclusively licensed from Algeta ASA, in patients ... its primary endpoint by significantly improving overall survival.  Based ...
    Cached Medicine Technology:University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 2University Hospitals Seidman Cancer Center Opens: First Cancer Hospital in Northeast Ohio Offers Nation's Most Advanced Technology and Treatments 3Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 2Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone 3
    (Date:9/3/2015)... ... September 03, 2015 , ... ... cost increases for fully insured employer-sponsored health insurance plans, more employers are moving ... according to data released from the 2014 United Benefit Advisors (UBA) Health Plan ...
    (Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters Welcomes ... to announce the additional of Carol Wysham, MD, to their esteemed Board of ... Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson ...
    (Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
    (Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... responsibility concierges; simplifying responsibilities which can impact the delicate life balance between work ... situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® Emergency ...
    (Date:9/3/2015)... NJ (PRWEB) , ... September 03, 2015 , ... ... today that AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s solution for ... been named a “KMWorld 2015 Trend-Setting Product”. This is the fifth consecutive ...
    Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4
    ... ... can help to prevent cavities. , ... Delray Beach, FL (PRWEB) July 8, 2009 -- Cavities are a persistent problem for ... to prevent them, according to Delray Beach, Florida-based dentist Dr. Craig Spodak, is to use ...
    ... 7 iMedX Inc., a leading healthcare software and services ... With this acquisition, iMedX expands its reach into the hospital ... companies in the United States. , , Based just ... systems across the country, utilizing a labor force of over ...
    ... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in ... today that its Board of Directors has retained Emerging Growth ... in evaluating strategic alternatives with a focus on acquisitions that ... believe that the scope of our product offerings and broad ...
    ... engineering David Bruce will participate in a multi-university Energy ... the U.S. Department of Energy. The Center for Atomic-Level ... new catalysts for the production of clean fuels and ... of CALCD, combined with those of 45 other new ...
    ... (Nasdaq: XTNT ) today announced that it has postponed ... at 9:00 a.m. Pacific Time on Thursday, July 9, 2009. ... August 3, 2009. , , On May 15, ... approved a Plan of Complete Liquidation and Dissolution of the Company ...
    ... (ZixCorp(R)), (Nasdaq: ZIXI ), the leader in hosted ... corporate update by its chief executive officer, Rick Spurr. , ... ZixCorp and we are on target to report within the ... are that we should meet our revenue guidance of $7.3 ...
    Cached Medicine News:Health News:South Florida Dentist Dr. Craig Spodak Recommends Artificial Sweetener Xylitol to Help Prevent Cavities 2Health News:iMedX Announces Acquisition of Medware Inc. 2Health News:OmniComm Systems, Inc. Retains Emerging Growth Equities, Ltd., as its Strategic Financial Advisor 2Health News:OmniComm Systems, Inc. Retains Emerging Growth Equities, Ltd., as its Strategic Financial Advisor 3Health News:DOE funds Clemson University clean energy research 2Health News:XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 3Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 4
    9 mm wide tip. 35 mm from angle to tip....
    Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
    Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
    Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
    Medicine Products: